Vcare PharmaTech Completes Full Participant Enrollment in Phase III Clinical Trial of VC005 Topical Gel, Balanced, Highly Selective New-Generation JAK1 Inhibitor, for Atopic Dermatitis
Published Time:
2026-10-20 17:57
Source:
Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) recently announced that its self-developed VC005 topical gel, balanced, highly selective new-generation JAK1 inhibitor for the treatment of mild-to-moderate atopic dermatitis (AD) in adults and adolescents, has successfully completed full participant enrollment in its Phase III clinical trial. This milestone marks steady progress for the topical product toward the NDA.
As a core asset in Vcare PharmaTech’s autoimmune pipeline, VC005 topical gel is administered topically to act directly on lesional skin. It delivers local therapeutic effects with minimal systemic exposure. While optimizing anti-inflammatory efficacy, the gel relieves pruritus more rapidly and maximizes medication safety. It achieves an improved clinical balance between maximal efficacy and favorable tolerability, catering to the needs of long-term, intermittent topical treatment for patients with mild-to-moderate AD. The enrolled Phase III study is a multicenter, randomized, double-blind, placebo-controlled trial. It will further validate the efficacy and safety of VC005 gel in a larger cohort of adult and adolescent subjects with mild-to-moderate AD, generating core evidence for subsequent new drug registration and filing.
About VC005 Topical Gel
VC005 is a balanced, highly selective next-generation JAK1 inhibitor. It exerts potent inhibition of JAK1 combined with moderate inhibition of TYK2 to target the Th2/Th1/Th17 inflammatory axes for improved overall therapeutic efficacy. Currently, both oral and topical formulations in multiple strengths have been developed, forming a product portfolio covering a wide range of indications. The VC005 topical gel adopts a unique pharmaceutical base, it supports high drug loading while maintaining robust stability, favorable safety profile without irritation, and a light, refreshing gel texture to improve patient adherence.In the completed Phase II clinical trial for mild-to-moderate atopic dermatitis, VC005 topical gel demonstrated notable pruritus relief and lesion improvement at the early stage of treatment. Pruritus relief was observed on Day 1, with an approximate 14% reduction in the mean NRSfor pruritus within 12 hours. Around 30% of subjects achieved ≥50% improvement in eczema area and severity index (EASI-50 response) after one week of dosing, translating to meaningful improvements in patients’ quality of life. In terms of safety, the incidence of TRAEswas lower than that of the vehicle group, with no SARsreported and favorable patient tolerability. Pharmacokinetic data showed extremely low plasma exposure, even lower in adolescent populations, with no drug accumulation. VC005 is expected to address the black box warning concerns associated with marketed topical agents of the same target.
About Atopic Dermatitis
Atopic dermatitis (AD) is a chronic, recurrent, inflammatory skin disease characterized by dry skin, intense pruritus, and eczematous rashes, which severely impacts patients' quality of life. Epidemiologically, the global prevalence of AD is approximately 230 million people. In China, the prevalence of AD among adults ranges from 2% to 8%, with over 70 million patients, including 67% with mild cases and 33% with moderate-to-severe cases. According to F&S forecasts, the number of patients will continue to grow at a CAGRof 1.7% from 2025 to 2030. Traditional therapeutic drugs, such as glucocorticoids, are associated with numerous adverse reactions and fail to provide long-term benefits, making it difficult to achieve effective and stable disease control. In contrast, topical small-molecule JAK1-targeted inhibitors are non-glucocorticoid immunosuppressants, which are expected to retain therapeutic efficacy with further improvement in the medication safety for patients with mild-to-moderate symptoms.
Disclaimer
1.This press release shares cutting‑edge R&D progress of the Company for informational purposes only and is not intended for advertising. Information herein is not directed at patients and is for reference by healthcare professionals only.
2.Nothing in this press release constitutes a recommendation for any medicinal product and/or indication.
3.All information contained herein is for reference only. Company press releases and announcements shall in no way substitute for professional medical advice and shall not be construed as medical guidance. Please consult physicians or other qualified healthcare professionals for disease‑specific diagnosis and treatment advice.
4.As of the release date of this document, VC005 Topical Gel have not obtained marketing approval from the NMPA.
5.This press release may contain certain forward‑looking statements. Such statements inherently carry substantial risks and uncertainties. Words including “anticipate”, “believe”, “forecast”, “expect”, “intend” and other similar expressions in connection with the Company constitute forward‑looking statements. The Company assumes no obligation to update such predictive statements on an ongoing basis.
Forward‑looking statements are based on management’s current views, assumptions, expectations, estimates, forecasts and understanding of future events as of the time of issuance. They are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond the Company’s control and difficult to predict. Accordingly, actual outcomes may differ materially from those reflected in forward‑looking statements due to future changes and developments in our business, competitive landscape, political, economic, legal and social conditions.
Neither the Company nor its directors, employees or agents shall bear any liability for (a) any obligation to correct or update forward‑looking statements published on this website; and (b) any liability arising from the non‑realization or inaccuracy of any forward‑looking statements.
Related News
18
2024
/
11
Jiangsu Vcare Selected Among "2024 China’s Top 500 Hidden Unicorn Enterprises"
At the 2024 China Hidden Unicorn 500 Summit, theDevelopment Report on China’s Top 500 Hidden Unicorn Enterprises 2024was released.Jiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) debuted on this list, showcasing its strong technical accumulation and continuous innovation in independent R&D of innovative drugs and full-chain CRO/CDMO services for pharmaceuticals.
01
2024
/
11
Recently, the Nanjing Municipal Science and Technology Bureau announced the acceptance results of 2024 provincial-level engineering research centers and academician workstations. The"Jiangsu (Vcare) Chemical Innovative Drug Engineering Research Center", established byJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare), successfully passed project acceptance.
28
2024
/
10
Jiangsu Vcare Included in "2024 Jiangsu Provincial Sci-Tech Enterprise Listing Cultivation Program"
Recently, the Jiangsu Provincial Department of Science and Technology announced the "2024 Proposed Enterprises for Provincial Sci-Tech Enterprise Listing Cultivation Program," withJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) successfully included.
23
2024
/
10
Jiangsu Vcare Selected Among "Top 100 China Pharma Innovation Seed Enterprises 2024"
Recently, the "Top 100 China Pharma Innovation Seed Enterprises 2024" list was released, withJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) ranked in the second tier. This list, compiled by a non-governmental organization, evaluates enterprises based on innovation foundation, process, and outcomes—using patent data, clinical trial data, etc.—selected from over 5,000 Chinese pharmaceutical companies.
22
2024
/
10
Jiangsu Vcare's Oral Treatment VC005 for Atopic Dermatitis enters Phase III Clinical Study
VC005 tablets, developed by Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare), is a new-generation highly selective JAK1 inhibitor. The oral treatment of moderate-to-severe atopic dermatitis has initiated a Phase III clinical trial. It is a multicenter, randomized, double-blind, placebo parallel-controlled Phase III clinical study, aiming to evaluate the efficacy and safety of VC005 tablets for adult patients with moderate-to-severe atopic dermatitis. The trial is led by the Institute of Dermatology, Chinese Academy of Medical Sciences.
17
2024
/
10
Jiangsu Vcare's New-generation TRK Inhibitor VC004 Obtains IND Approval from the US FDA
On October 16, 2024, Jiangsu Vcare Pharmatech Co., Ltd. (referred to as "Jiangsu Vcare")'s independently developed new-generation anti-resistant TRK inhibitor VC004 achieved a significant milestone progress, and the project officially obtained the Investigational New Drug (IND) permission from the US Food and Drug Administration (FDA). This fully demonstrates Jiangsu Vcare's excellent drug research and development capabilities and is a successful practice of the company's strategies based on original innovation, high-quality standards, and a global layout.